Enhanced interaction of patients' lymphocytes with human dermal microvascular endothelial cell cultures in active Adamantiades-Behcet disease

Treudler, Regina

doi:10.1001/archderm.132.11.1323

Cited by 8 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It also inhibits the synthesis of glycoproteins, some of them functioning as adhesion molecules for lymphocytes to the target cells [9]. In Adamantiades-Behçet’s disease an elevated adhesion of lymphocytes [10]and neutrophils [11]on endothelial cells has been observed. In addition, MMF leads to a release of tumor necrosis factor α promoting the production of the anti-inflammatory interleukin 10 [12], whereas in Adamantiades-Behçet’s disease tumor necrosis factor α and interleukin 10 levels are also elevated [13].…”

Section: Discussionmentioning

confidence: 99%

Mycophenolate Mofetil Is Ineffective in the Treatment of Mucocutaneous Adamantiades-Behçet’s Disease

Adler¹,

Mansmann

Zouboulis³

2001

Dermatology

View full text Add to dashboard Cite

Background: Cyclosporine A and azathioprine are effective on mucocutaneous lesions in Adamantiades-Behçet’s disease. Mycophenolate mofetil (MMF) is a drug resembling their activity but with comparably negligible adverse reactions. Objective: A prospective clinical proof-of-principle study was conducted to investigate the effectiveness and toxicity of MMF in mucocutaneous Adamantiades-Behçet’s disease. Methods: Thirty patients were to be treated with MMF 2 g/day p.o. for 6 months, in combination with prednisolone 30 mg/day p.o. during the first month of treatment. Inefficacy was followed by an increase in MMF dose to 3 g/day. The primary efficacy variable was the decrease in the disease activity index (DAI) according to a modified variant of the Iran Behçet’s Disease Dynamic Activity Measure system. Results: The study was interrupted due to inefficacy of the compound after the intermediate evaluation of the first 6 patients (aged 37.0 ± 7.7 years with disease duration of 10.0 ± 8.9 years) as required by the ethical committee. Although an improvement of the DAI from 5.2 ± 3.5 to 1.3 ± 0.5 was found after the first month of combination treatment, withdrawal of prednisolone led to quick relapses with a new index increase (3.0 ± 3.5). The treatment was discontinued in 3 patients after 3 months, in 2 patients after 4 months and in another one after 5 months due to deterioration of the disease. Introduction of interferon α_2a (3 × 9 million IU 3×/week s.c.) in 3 patients decreased the activity index from 4.0 ± 1.0 to 0.0 ± 0.0. No adverse effects were detected under MMF treatment. Conclusion: MMF (2–3 g/day) is unable to control the signs of mucocutaneous Adamantiades-Behçet’s disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Mycophenolate Mofetil Is Ineffective in the Treatment of Mucocutaneous Adamantiades-Behçet’s Disease

Adler¹,

Mansmann

Zouboulis³

2001

Dermatology

View full text Add to dashboard Cite

show abstract

“…IL-8 is a sensitive chemokine; its serum levels document leucocyte recruitment and interaction with blood vessel endothelial cells [15, 16]. The latter has been suggested as the initial pathological sign in the development of lesions in Adamantiades-Behçet’s disease [1, 7, 17, 18, 19]. …”

Section: Discussionmentioning

confidence: 99%

Adamantiades-Behçet’s Disease: Serum IL-8 Is a More Reliable Marker for Disease Activity than C-Reactive Protein and Erythrocyte Sedimentation Rate

et al. 2000

View full text Add to dashboard Cite

Background: Interleukin 8 (IL-8) has recently been under focused investigation because of its possible participation in the evolution of Adamantiades-Behçet’s disease. Objective: The reliability of IL-8 as a serological marker for the activity of the disease was investigated in a prospective consecutive trial of 34 cases. Methods: The activity of the disease was clinically evaluated by the number of actively involved organ systems registered on the day of blood sampling and by the presence of oral aphthous ulcers. Serum IL-8 levels were compared to C-reactive protein (CRP) values and the erythrocyte sedimentation rate. Results: An association of IL-8 levels with the activity of the disease was detected when compared with both the number of active clinical signs (p = 0.024) and the presence of oral aphthous ulcers (p = 0.002). In contrast, no association of CRP and sedimentation rate with the activity of the disease could be detected. A weak correlation of IL-8 levels with sedimentation rate values at 2 h was found (R = 0.37, p = 0.032). Conclusion: Our results confirm previous data concerning the significance of IL-8 and, in addition, they provide first evidence for the reliability of IL-8 as a serological marker for assessment of the activity of Adamantiades-Behçet’s disease in the follow-up of clinical and therapeutic studies.

show abstract

“…It has been suggested that immunoactive cells such as T cells infiltrate into the affected regions with activation of circulating T and B lymphocytes, followed by chemotaxis of neutrophils or vice versa [16, 17, 18]. The histologic features are characterized by inflammatory processes in the arteries and veins and thrombosis as a result of vasculitis of the vasa vasorum with thickening of the media [16, 17, 19, 20].…”

Section: Discussionmentioning

confidence: 99%

Increased Plasma Adrenomedullin Levels in Patients with Behçet’s Disease

Evereklioğlu

Yürekli²,

et al. 2000

Dermatology

View full text Add to dashboard Cite

Background: Behçet’s disease (BD) is a chronic systemic inflammatory disorder affecting multiple organs with a generalized vasculitis of arteries and veins. Endothelial dysfunction is one of the prominent features of BD. Adrenomedullin (AM) is a peptide produced not only in normal adrenal medulla but also in the vascular smooth muscle cells and endothelial cells, and its role in the course of BD has not been previously described. Objective: To detect changes of plasma AM concentrations in patients with BD compared with age- and sex-matched healthy subjects by using high-performance liquid chromatography (HPCL). We also investigated if disease activity or the duration of BD correlates with AM levels. Methods: Forty-two consecutive patients with BD (38.5 ± 11.1 years, 19 male and 23 female) and 20 healthy age- and sex-matched control subjects (39.5 ± 10.9 years, 8 male and 12 female) were included in this study. We measured plasma AM levels by HPCL, and acute-phase reactants including α₁-antitrypsin and α₂-macroglobulin, neutrophil count and the erythrocyte sedimentation rate. Results: Mean ± SD plasma AM levels in patients with BD (73.22 ± 25.55 pmol/l) were significantly higher (p < 0.001) than in healthy control volunteers (21.35 ± 12.37 pmol/l). Patients with active BD had similar plasma AM concentrations (79.32 ± 21.89 pmol/l) with patients with inactive disease (67.44 ± 29.92 pmol/l). On the other hand, patients with longer duration of the disease (mean duration, 13.9 ± 3.8 years) had significantly higher plasma AM levels (83.99 ± 19.71 pmol/l; p = 0.005) than patients (62.45 ± 26.57 pmol/l) with shorter duration of the disease (mean duration, 5.5 ± 2.3 years). All acute-phase reaction parameters were found to be significantly increased in the active disease. Conclusion: Considering its endothelial cell implications, AM may be involved in reparatory vessel endothelium mechanisms, especially in the chronic disease.

show abstract

Enhanced interaction of patients' lymphocytes with human dermal microvascular endothelial cell cultures in active Adamantiades-Behcet disease

Cited by 8 publications

References 0 publications

Mycophenolate Mofetil Is Ineffective in the Treatment of Mucocutaneous Adamantiades-Behçet’s Disease

Mycophenolate Mofetil Is Ineffective in the Treatment of Mucocutaneous Adamantiades-Behçet’s Disease

Adamantiades-Behçet’s Disease: Serum IL-8 Is a More Reliable Marker for Disease Activity than C-Reactive Protein and Erythrocyte Sedimentation Rate

Increased Plasma Adrenomedullin Levels in Patients with Behçet’s Disease

Contact Info

Product

Resources

About